“Securing a patent in Australia is a strategic achievement for Mucocort and a crucial step in our efforts to establish a presence in a key market. This strengthens our global position and unlocks new growth opportunities,” says Jean Lycke, Project Manager at Mucocort.

Mucocort has developed M045A, an innovative mucoadhesive “patch” for the treatment of oral aphthous ulcers.

The patent grants Mucocort exclusive rights in the Australian market. It also paves the way for strategic collaborations with leading medtech companies, further accelerating the company’s expansion and market presence, it states.